{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:37:54Z","timestamp":1791999474320,"version":"4.4.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Peyronie\u2019s disease (PD) involves the formation of fibrous scar tissue in the penis, causing pain, deformity, and significant psychological and sexual distress. Intralesional injection of collagenase Clostridium histolyticum (CCH) has emerged as a promising non-surgical treatment, though patients may experience complications and require multiple clinic visits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>This study aims to evaluate patient compliance with CCH therapy, compare outcomes between compliant and non-compliant groups, and identify reasons for non-compliance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This IRB-approved retrospective study analyzed patients with PD between 2017 and 2023. Patients were evaluated by a fellowship-trained andrologist. Patients who elected to have intralesional CCH were initially offered four cycles of treatment, with compliance defined as completing at least four cycles or achieving satisfactory results with fewer cycles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>Data on demographics, disease characteristics, treatment modalities, compliance, and outcomes were extracted from electronic medical records, and causes of non-compliance were identified. Outcomes and complications were compared between compliant and non-compliant groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two hundred and ninety-two PD patients elected to have an intralesional injection of collagenase CCH. Among these, 51.4% completed four treatment cycles, 14.7% received more than four cycles, and 33.9% received fewer than four cycles. The overall compliance rate for injection therapy, including those satisfied with fewer cycles, was 70.89%. Mean pre-treatment curvature for 292 patients was 46.77\u2009\u00b1\u200914.26 degrees. Compliant patients showed a greater percent of curvature reduction (median 44.44 (IQR 34.17) vs 33.33 (IQR 44.17), P\u2009=\u2009.034) and less post-treatment curvature in degree (median 25.00 (IQR 17.02) vs 30.00 (IQR 23.75), P\u2009=\u2009.032) compared to non-compliant patients. Common reasons for incomplete treatment included adverse effects (15.1%), early satisfaction with results (14.1%), and unknown factors (45.4%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Compliance with CCH therapy for PD significantly impacts treatment outcomes. Healthcare providers should address factors contributing to non-compliance. Qualitative studies are recommended to gain deeper insights into non-compliant patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>This study analyzed compliance in a large cohort of PD patients and compared outcomes between compliant and non-compliant groups. However, missing data in the non-compliant group and the bias between compliant and non-compliant patients in this retrospective study are major notable limitations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Overall compliance rate for CCH injection therapy was 70.89%. Greater curvature reduction was demonstrated in compliant patients. Common reasons for incomplete treatment included adverse effects (15.1%), early satisfaction with results (14.1%), and unknown factors (45.4%). However, missing data and bias from retrospective design are major limitations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdaf051","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T09:09:37Z","timestamp":1744621777000},"page":"794-798","source":"Crossref","is-referenced-by-count":2,"title":["Are patients undergoing intralesional collagenase <i>Clostridium histolyticum<\/i> injection therapy for Peyronie\u2019s disease compliant? A 7-year analysis from a tertiary care men\u2019s health center"],"prefix":"10.1093","volume":"22","author":[{"given":"Supanut","family":"Lumbiganon","sequence":"first","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, Khon Kaen University , 40000 ,","place":["Thailand"]},{"name":"Department of Urology, University of California , Irvine, CA, 92868 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , Irvine, CA, 92868 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5396-1364","authenticated-orcid":false,"given":"Muhammed A M","family":"Hammad","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , Irvine, CA, 92868 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-896X","authenticated-orcid":false,"given":"Elia","family":"Abou Chawareb","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , Irvine, CA, 92868 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faysal A","family":"Yafi","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California , Irvine, CA, 92868 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"3","key":"2025061006465800800_ref1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.5534\/wjmh.200065","article-title":"The natural history of Peyronie\u2019s disease","volume":"39","author":"Di Maida","year":"2021","journal-title":"World J Mens Health"},{"issue":"2","key":"2025061006465800800_ref2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajur.2015.04.019","article-title":"All about Peyronie\u2019s disease","volume":"2","author":"Hussein","year":"2015","journal-title":"Asian Journal of Urology"},{"issue":"2","key":"2025061006465800800_ref3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/0092623X.2014.985351","article-title":"The impact of Peyronie\u2019s disease on the patient: gaps in our current understanding","volume":"42","author":"Goldstein","year":"2016","journal-title":"Journal of Sex & Marital Therapy"},{"issue":"3","key":"2025061006465800800_ref4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1743-6109.2012.02999.x","article-title":"Psychological impact of Peyronie\u2019s disease: a review","volume":"10","author":"Nelson","year":"2013","journal-title":"J Sex Med"},{"issue":"3","key":"2025061006465800800_ref5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.21037\/tau.2016.05.14","article-title":"Psychological aspects of Peyronie\u2019s disease","volume":"5","author":"Terrier","year":"2016","journal-title":"Transl Androl Urol"},{"issue":"3","key":"2025061006465800800_ref6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/j.1939-4640.2000.tb03387.x","article-title":"Peyronie\u2019s disease: etiology, medical, and surgical therapy","volume":"21","author":"Hellstrom","year":"2000","journal-title":"J Androl"},{"issue":"2","key":"2025061006465800800_ref7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.sxmr.2019.06.004","article-title":"The etiology of Peyronie\u2019s disease: pathogenesis and genetic contributions","volume":"8","author":"Sharma","year":"2020","journal-title":"Sexual Medicine Reviews"},{"issue":"4","key":"2025061006465800800_ref8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/andr.12058","article-title":"Therapeutic advances in the treatment of Peyronie\u2019s disease","volume":"3","author":"Yafi","year":"2015","journal-title":"Andrology"},{"issue":"2","key":"2025061006465800800_ref9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.sxmr.2020.12.004","article-title":"Platelet-rich plasma injections for erectile dysfunction and Peyronie\u2019s disease: a systematic review of evidence","volume":"10","author":"Alkandari","year":"2022","journal-title":"Sexual Medicine Reviews"},{"issue":"4","key":"2025061006465800800_ref10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/14712598.2017.1295034","article-title":"Stem cell therapy for the treatment of Peyronie\u2019s disease","volume":"17","author":"Dellis","year":"2017","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"2025061006465800800_ref11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.urology.2023.01.061","article-title":"Stem-cell, shockwave, and platelet rich plasma therapy for the treatment of erectile dysfunction and Peyronie\u2019s disease: a survey of clinics across the USA","volume":"178","author":"Thomas","year":"2023","journal-title":"Urology"},{"issue":"3","key":"2025061006465800800_ref12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41443-021-00430-x","article-title":"Trends in treatment of Peyronie\u2019s disease in adult men in the United States from 2008 to 2017\u2014results from an encounter and claims database","volume":"34","author":"Moghalu","year":"2022","journal-title":"Int J Impot Res"},{"issue":"1","key":"2025061006465800800_ref13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie's disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","journal-title":"J Urol"},{"issue":"2","key":"2025061006465800800_ref14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00345-019-02791-x","article-title":"Management of Peyronie\u2019s disease with collagenase Clostridium histolyticum in the acute phase","volume":"38","author":"El-Khatib","year":"2020","journal-title":"World J Urol"},{"issue":"9","key":"2025061006465800800_ref15","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jsxm.2019.06.010","article-title":"Comparative cost-effectiveness of surgery, collagenase Clostridium histolyticum, and penile traction therapy in men with Peyronie\u2019s disease in an era of effective clinical treatment","volume":"16","author":"Wymer","year":"2019","journal-title":"J Sex Med"},{"issue":"5","key":"2025061006465800800_ref16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/JU.0000000000003634","article-title":"Comparison of collagenase Clostridium histolyticum to surgery for the management of Peyronie\u2019s disease: a randomized trial","volume":"210","author":"Green","journal-title":"J Urol"},{"issue":"1","key":"2025061006465800800_ref17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.urology.2023.10.022","article-title":"The discontinuation rate with collagenase Clostridium histolyticum for Peyronie\u2019s disease in a high-volume practice is unexpectedly high: identifying opportunities for patient care improvement","volume":"183","author":"Lehner","year":"2024","journal-title":"Urology"},{"issue":"4","key":"2025061006465800800_ref18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.sxmr.2019.05.001","article-title":"Discontinuation from collagenase Clostridium histolyticum therapy for Peyronie\u2019s disease: review and single-center cohort analysis","volume":"7","author":"Amighi","year":"2019","journal-title":"Sex Med Rev"},{"issue":"1","key":"2025061006465800800_ref19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","article-title":"Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie\u2019s disease","volume":"100","author":"Anaissie","year":"2017","journal-title":"Urology"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/5\/794\/62925088\/qdaf051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/5\/794\/62925088\/qdaf051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T10:47:01Z","timestamp":1749552421000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/22\/5\/794\/8113152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,4,14]]},"published-print":{"date-parts":[[2025,5,10]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdaf051","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,14]]}}}